Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurie Markman

Showing results (31-40 of 413) with videos related to

Pageof 42
Sort By:
Cleveland Clinic Journal of Medicine|May 23, 2002
Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'?Maurie Markman
Expert Review of Anticancer Therapy|July 13, 2002
Role of chemotherapy in the management of ovarian cancerMaurie Markman
Oncology|May 11, 2012
Palliation of symptomatic malignant ascites: an (often) unmet needMaurie Markman
IRB|July 30, 2004
What must research subjects be told regarding the results of completed randomized trials?Maurie Markman
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Hormonal therapy of endometrial cancerMaurie Markman
Current Oncology Reports|June 11, 2005
Unique issues in the development of "targeted" antineoplastic pharmaceutical agentsMaurie Markman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Optimal management of recurrent ovarian cancerMaurie Markman
Oncology|December 17, 2013
Continuation or reintroduction of an antineoplastic strategy after documented disease progressionMaurie Markman
Gynecologic Oncology|December 14, 2011
Trends in treatment of advanced epithelial ovarian cancer in the Medicare populationMaurie Markman
Drugs|April 18, 2008
Pharmaceutical management of ovarian cancer : current statusMaurie Markman
Pageof 42

Showing results (31-40 of 413) with videos related to

Sort By:
Pageof 42
Cleveland Clinic Journal of Medicine|May 23, 2002
Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'?Maurie Markman
Expert Review of Anticancer Therapy|July 13, 2002
Role of chemotherapy in the management of ovarian cancerMaurie Markman
Oncology|May 11, 2012
Palliation of symptomatic malignant ascites: an (often) unmet needMaurie Markman
IRB|July 30, 2004
What must research subjects be told regarding the results of completed randomized trials?Maurie Markman
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Hormonal therapy of endometrial cancerMaurie Markman
Current Oncology Reports|June 11, 2005
Unique issues in the development of "targeted" antineoplastic pharmaceutical agentsMaurie Markman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Optimal management of recurrent ovarian cancerMaurie Markman
Oncology|December 17, 2013
Continuation or reintroduction of an antineoplastic strategy after documented disease progressionMaurie Markman
Gynecologic Oncology|December 14, 2011
Trends in treatment of advanced epithelial ovarian cancer in the Medicare populationMaurie Markman
Drugs|April 18, 2008
Pharmaceutical management of ovarian cancer : current statusMaurie Markman
Pageof 42